Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IsKia: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Eligible for ASCT
NCT04483739Phase 3Active, not recruiting
- Start
- Sep 2020
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of isatuximab in multiple myeloma (MM). Started Sep 2020; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04483739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483739.